Advertisement
New Options for Treating Opioid Addiction

New Options for Treating Opioid Addiction

The quest for improved outcomes in the treatment of opioid addiction is accelerating on several fronts. Buprenorphine is widely used for the treatment of opioid dependence. Studies have shown that it’s an effective means to reduce opioid cravings and help prevent withdrawal symptoms. However, there is still potential for diversion and/or abuse of these drugs. As a result, researchers are working to develop new modes of administration to reduce these risks. Simultaneously, work is underway on other modalities of treatment, such as deep brain stimulation (DBS), as potential alternative therapies for treating opioid addiction. Medication Advances In June 2014, the FDA approved the first buprenorphine and naloxone buccal film that is indicated for the maintenance treatment of opioid dependence. Created by BioDelivery Sciences International, the product works differently from existing sublingual film formulations of buprenorphine and naloxone. The new product features buccal film that uses a proprietary muco-adhesive technology in the form of a thin film that sticks to the inside of the cheek and dissolves minutes after placement. Clinical studies suggest this formulation provides twice the bioavailability of buprenorphine when compared with sublingual formulations. This helps halve the dose of drug required and, thus, potentially cuts the risk of abuse and diversion. A separate novel approach to the delivery of buprenorphine involves a subdermal implant formulation for the maintenance treatment of opioid dependence. The experimental implant is designed to deliver continuous, around-the-clock blood levels of buprenorphine for 6 months following a single treatment. The subdermal implant is made from a mixture of ethylene-vinyl acetate and a drug substance that is released at a slow and steady rate. It...
CHEST 2014

CHEST 2014

New research is being presented at CHEST 2014, the annual meeting of the American College of Chest Physicians, from October 25 to 30 in Austin, TX.   Meeting Highlights Portable Ventilator Improves Health Status Trends in ARDS-Related Mortality CPAP & Sexual Quality of Life A Wrist Activity Monitor for COPD Patients Geriatric Syndromes, ADLs, & Health Status in COPD Adding ECMO to CPR Predicting Time to Wean in ARDS Transthoracic Ultrasound for CAP in the ED A Novel Approach to ED Thoracotomy Training ECMO for Refractory ARDS   News from CHEST 2014 Stopping Inhaled Steroids in COPD Feasible Mixed Results With Combo Therapy for PAH CHEST: Lower ARDS Mortality, PAH, Jerky Legs Lung Donation After Cardiac Death Shows Promise Benefits of Aclidinium Persist to 1 Year for COPD Tiotropium Showing Promise in Pediatric Asthma Implant Eliminates External Pump in Pulmonary Hypertension Common Sense Ebola Measures Save Lives in Africa, Teach US Once-Daily Combo Outperforms Twice-Daily in COPD Ebola, the Asthma Epidemic, and the Microbiome at CHEST 2014   More From CHEST 2014 Meeting Info Program Clinical Resource Center Destination and Travel Exhibitors and Support...
Get Connected

Get Connected

Get the edge on your colleagues by receiving updates directly from the Physician’s Weekly editors in multiple ways. Sign up for our weekly e-newsletter Subscribe to our RSS Feed Like us on Facebook Check us out on Google+ Follow us on Twitter Join the conversation on...
[ HIDE/SHOW ]